Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
| ▸ | NMT1 | P30419 | 1/20 | 0.33 |
| ▸ | QPCT | Q16769 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23206356 | 0.76 | HRH3 (0.35) | HRH3HRH4KDM2BNMT1QPCT | |
| SCHEMBL22302587 | 0.76 | HRH3 (0.43) | HRH3HRH4KDM2BQPCTACHE | |
| SCHEMBL22180827 | 0.74 | HRH3 (0.43) | HRH3HRH4NMT1ACHE | |
| SCHEMBL22198925 | 0.74 | KDM2B (0.52) | HRH3HRH4KDM2BQPCTCHRM3 | |
| SCHEMBL13681917 | 0.70 | KDM2B (0.45) | HRH3HRH4KDM2BQPCTCHRM3 | |
| SCHEMBL20644871 | 0.68 | CPB1 (0.35) | HRH3KDM2BACHECHRM3 | |
| SCHEMBL23519498 | 0.64 | HDAC3 (0.33) | HRH3HRH4NMT1 | |
| SCHEMBL26231867 | 0.63 | SCN2A (0.39) | QPCT | |
| SCHEMBL13681927 | 0.62 | KCNH2 (0.42) | HRH3KDM2BCHRM3 | |
| SCHEMBL12247669 | 0.62 | PHF8 (0.49) | KDM2BQPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210101887-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | ASTEX THERAPEUTICS LIMITED (GB) | 2021-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210101887-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION AND PROCESS FOR MAKING THEM | MDM2, TP53, TP53BP1 | HRH3 4108/4885HRH4 4136/4885KDM2B 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.